Hangzhou-based Chinese biotechnology company METiS Pharmaceuticals is set to launch a $200 million initial public offering (IPO) in Hong Kong, focusing on AI-driven drug development and distribution systems.
The company aims to kick off its IPO process by the end of 2025, with financial advisors already in place.
METiS is leveraging artificial intelligence technologies to revolutionize drug delivery, particularly in cell and gene therapies (CGT) and nucleic acid-based treatments.
Chinese Biotech METiS Targets $200M IPO
With innovative solutions like AiLNP (lipid nanoparticle) and AiRNA (mRNA design) platforms, the company is positioned at the forefront of digital transformation in the biotech sector.
Having raised approximately $3 billion from major investors such as Sequoia China and China Life Insurance, METiS is now looking to capitalize on Hong Kong’s rapidly growing biotechnology ecosystem.
The IPO plans reflect the company’s strategy to tap into the region’s investment climate, and a successful listing could further cement Hong Kong’s position as a global biotech innovation hub.
